# Canakinumab in Patients With COVID-19 and Type 2 Diabetes

Study · id `cardio:ct-nct04510493` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04510493](<https://clinicaltrials.gov/study/NCT04510493>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04510493

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 116 participants.

## Technical summary

Registry record NCT04510493. Randomized; double masking; primary purpose treatment. Start 2020-10-23 (actual); primary completion 2021-08-17 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 116 participants (enrolled count; ClinicalTrials.gov record NCT04510493, source copy `cardio:ctgov-nct04510493-2021-09-08`, retrieved 2026-10-26)
- Started: 2020-10-23 (actual) (ClinicalTrials.gov record NCT04510493, source copy `cardio:ctgov-nct04510493-2021-09-08`, retrieved 2026-10-26)
- Primary completion: 2021-08-17 (actual) (ClinicalTrials.gov record NCT04510493, source copy `cardio:ctgov-nct04510493-2021-09-08`, retrieved 2026-10-26)
- Completion: 2021-08-17 (actual) (ClinicalTrials.gov record NCT04510493, source copy `cardio:ctgov-nct04510493-2021-09-08`, retrieved 2026-10-26)
- Countries: Switzerland (ClinicalTrials.gov record NCT04510493, source copy `cardio:ctgov-nct04510493-2021-09-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04510493-2021-09-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Canakinumab in Patients With COVID-19 and Type 2 Diabetes
- Acronym: CanCovDia
- Condition: Coronavirus Infection
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Canakinumab
- Intervention (Drug): Placebo
- Lead sponsor: University Hospital, Basel, Switzerland
- Lead sponsor class: OTHER
- Collaborator: Novartis
- Collaborator class: INDUSTRY
- Collaborator: Swiss National Science Foundation
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: University Hospital, Basel, Switzerland (`cardio:org-university-hospital-basel-switzerland`)
- Registry lists this organization as a collaborator: Novartis (`cardio:novartis`)
- Registry lists this organization as a collaborator: Swiss National Science Foundation (`cardio:org-swiss-national-science-foundation`)

## Provenance

Content hash: fac51ff4a7f7e2d5d995488e488e7c7b83ac24898302353a5a78dcaa72c823b0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
